In recent years, the advent of immune checkpoint inhibitors (ICIs), specifically programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) antibodies, has dramatically altered the therapeutic landscape for NSCLC due to their superior efficacy compared to conventional chemotherapy (2–4). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.